Summary
IDEXX Laboratories, Inc. reported a solid third quarter for 2005, with revenue increasing by 18% year-over-year to $158.1 million. This growth was primarily driven by its Companion Animal Group (CAG), which saw an 18.3% revenue increase, fueled by strong performance in laboratory and consulting services, instruments and consumables, and rapid assay products. The Food Diagnostics Group (FDG) also showed significant growth, up 29.5%, largely due to acquisitions and increased sales of production animal products. While overall profitability showed a slight increase in operating income to $30.1 million, the net income experienced a slight decrease to $20.6 million compared to the prior year's $19.7 million for the quarter, and a decrease for the nine-month period. This was influenced by higher operating expenses, increased income tax rates, and a one-time benefit in the prior year's comparable period. The company's balance sheet remains strong, with cash and cash equivalents increasing to $57.8 million. IDEXX continued its share repurchase program, indicating confidence in its financial position and value. Management expressed optimism about future growth driven by new product development, market expansion, and strategic acquisitions, while acknowledging potential risks related to regulatory environments, supply chain dependencies, and competitive pressures.
Key Highlights
- 1Revenue grew 18% year-over-year to $158.1 million in Q3 2005.
- 2Companion Animal Group (CAG) revenue increased 18.3%, driven by laboratory services and instruments/consumables.
- 3Food Diagnostics Group (FDG) revenue surged 29.5%, boosted by acquisitions and production animal products.
- 4Operating income rose to $30.1 million, a 6.1% increase year-over-year.
- 5Net income for the quarter was $20.6 million, a slight decrease from $19.7 million in the prior year.
- 6The company repurchased $38.4 million worth of its common stock during the quarter.
- 7Cash and cash equivalents increased to $57.8 million as of September 30, 2005.